Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 7/2017

01-07-2017 | Hepatobiliary-Pancreas

Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma

Authors: Bang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, Po-Chin Liang, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng, Tiffany Ting-Fang Shih

Published in: European Radiology | Issue 7/2017

Login to get access

Abstract

Objectives

To correlate early changes in the parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) within 1 week of systemic therapy with overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC).

Methods

Eighty-nine patients with advanced HCC underwent DCE-MRI before and within 1 week following systemic therapy. The relative changes of six DCE-MRI parameters (Peak, Slope, AUC, Ktrans, Kep and Ve) of the tumours were correlated with OS using the Kaplan–Meier model and the double-sided log-rank test.

Results

All patients died and the median survival was 174 days. Among the six DCE-MRI parameters, reductions in Peak, AUC, and Ktrans, were significantly correlated with one another. In addition, patients with a high Peak reduction following treatment had longer OS (P = 0.023) compared with those with a low Peak reduction. In multivariate analysis, a high Peak reduction was an independent favourable prognostic factor in all patients [hazard ratio (HR), 0.622; P = 0.038] after controlling for age, sex, treatment methods, tumour size and stage, and Eastern Cooperative Oncology Group performance status.

Conclusions

Early perfusion changes within 1 week following systemic therapy measured by DCE-MRI may aid in the prediction of the clinical outcome in patients with advanced HCC.

Key points

• DCE-MRI is helpful to evaluate perfusion changes of HCC after systemic treatment.
• Early perfusion changes within 1 week after treatment may predict overall survival.
• High Peak reduction was an independent favourable prognostic factor after systemic treatment.
Literature
1.
Altekruse SF, McGlynn KA, Reichman ME (2009) Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 27:1485–1491CrossRefPubMedPubMedCentral
2.
3.
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMed
4.
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
5.
6.
Shao YY, Hsu CH, Cheng AL (2015) Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: are we getting there? World J Gastroenterol 21:10336–10347CrossRefPubMedPubMedCentral
7.
Corona-Villalobos CP, Halappa VG, Geschwind JF et al (2015) Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib. Eur Radiol 25:380–390CrossRefPubMed
8.
De Robertis R, Tinazzi Martini P, Demozzi E et al (2015) Prognostication and response assessment in liver and pancreatic tumors: the new imaging. World J Gastroenterol 21:6794–6808PubMedPubMedCentral
9.
Duffy AG, Ulahannan SV, Cao L et al (2015) A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterol J 3:453–461CrossRefPubMedPubMedCentral
10.
O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC (2012) Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol 9:167–177CrossRefPubMed
11.
Fischer MA, Kartalis N, Grigoriadis A et al (2015) Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis. Eur Radiol 25:3123–3132CrossRefPubMed
12.
13.
Jajamovich GH, Huang W, Besa C et al (2016) DCE-MRI of hepatocellular carcinoma: perfusion quantification with Tofts model versus shutter-speed model-initial experience. MAGMA 29:49–58CrossRefPubMed
14.
Pickles MD, Lowry M, Manton DJ, Turnbull LW (2015) Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators. Eur Radiol 25:1097–1106CrossRefPubMed
15.
Yuan Z, Li WT, Ye XD, Zhu HY, Peng WJ (2014) Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. Clin Transl Oncol 16:599–605CrossRefPubMed
16.
Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H (2015) Water-exchange-modified kinetic parameters from dynamic contrast-enhanced MRI as prognostic biomarkers of survival in advanced hepatocellular carcinoma treated with antiangiogenic monotherapy. PLoS One 10, e0136725CrossRefPubMedPubMedCentral
17.
Lee SH, Hayano K, Zhu AX, Sahani DV, Yoshida H (2015) Dynamic contrast-enhanced MRI kinetic parameters as prognostic biomarkers for prediction of survival of patient with advanced hepatocellular carcinoma: a pilot comparative study. Acad Radiol 22:1344–1360CrossRefPubMed
18.
Hsu CY, Shen YC, Yu CW et al (2011) Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil. J Hepatol 55:858–865CrossRefPubMed
19.
Mross K, Fasol U, Frost A et al (2009) DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 1:5CrossRefPubMedPubMedCentral
20.
Hsu C, Yang TS, Huo TI et al (2012) Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study. J Hepatol 56:1097–1103CrossRefPubMed
21.
Kim KA, Park MS, Ji HJ et al (2014) Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. J Magn Reson Imaging 39:286–292CrossRefPubMed
22.
Hoff BA, Bhojani MS, Rudge J et al (2012) DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model. NMR Biomed 25:935–942CrossRefPubMed
23.
Moestue SA, Huuse EM, Lindholm EM et al (2013) Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts. J Magn Reson Imaging 38:1043–1053CrossRefPubMed
24.
Gaustad JV, Simonsen TG, Smistad R, Wegner CS, Andersen LM, Rofstad EK (2015) Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging. BMC Cancer 15:900CrossRefPubMedPubMedCentral
25.
Chen B-B, Hsu C-Y, Yu C-W et al (2016) Dynamic contrast-enhanced MR imaging of advanced hepatocellular carcinoma: comparison with the liver parenchyma and correlation with the survival of patients receiving systemic therapy. Radiology 281:454–464CrossRefPubMed
26.
Bokacheva L, Rusinek H, Chen Q et al (2007) Quantitative determination of Gd-DTPA concentration in T1-weighted MR renography studies. Magn Reson Med 57:1012–1018CrossRefPubMed
27.
Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223–232CrossRefPubMed
28.
Leach MO, Brindle KM, Evelhoch JL et al (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92:1599–1610CrossRefPubMedPubMedCentral
29.
Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955–3964CrossRefPubMed
30.
van Laarhoven HW, Rijpkema M, Punt CJ et al (2003) Method for quantitation of dynamic MRI contrast agent uptake in colorectal liver metastases. J Magn Reson Imaging 18:315–320CrossRefPubMed
31.
Jiang T, Zhu AX, Sahani DV (2013) Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol 58:169–177CrossRefPubMed
32.
Goh V, Padhani AR (2006) Imaging tumor angiogenesis: functional assessment using MDCT or MRI? Abdom Imaging 31:194–199CrossRefPubMed
33.
Sahani DV, Jiang T, Hayano K et al (2013) Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol 6:51CrossRefPubMedPubMedCentral
34.
Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV (2008) Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 13:120–125CrossRefPubMed
35.
Jiang T, Kambadakone A, Kulkarni NM, Zhu AX, Sahani DV (2012) Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Investig Radiol 47:11–17CrossRef
36.
Yopp AC, Schwartz LH, Kemeny N et al (2011) Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. Ann Surg Oncol 18:2192–2199CrossRefPubMedPubMedCentral
37.
Jarnagin WR, Schwartz LH, Gultekin DH et al (2009) Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 20:1589–1595CrossRefPubMedPubMedCentral
38.
Zhu AX, Sahani DV, Duda DG et al (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027–3035CrossRefPubMedPubMedCentral
39.
Hayano K, Fuentes-Orrego JM, Sahani DV (2014) New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol 20:3059–3068CrossRefPubMedPubMedCentral
40.
Galbraith SM, Lodge MA, Taylor NJ et al (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 15:132–142CrossRefPubMed
41.
Sahani DV, Holalkere NS, Mueller PR, Zhu AX (2007) Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue—initial experience. Radiology 243:736–743CrossRefPubMed
42.
Donati OF, Do RK, Hötker AM et al (2015) Interreader and inter-test agreement in assessing treatment response following transarterial embolization for hepatocellular Carcinoma. Eur Radiol 25:2779–2788CrossRefPubMedPubMedCentral
43.
Chapiro J, Duran R, Lin M et al (2015) Early survival prediction after intra-arterial therapies: a 3D quantitative MRI assessment of tumour response after TACE or radioembolization of colorectal cancer metastases to the liver. Eur Radiol 25:1993–2003CrossRefPubMedPubMedCentral
Metadata
Title
Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma
Authors
Bang-Bin Chen
Chao-Yu Hsu
Chih-Wei Yu
Po-Chin Liang
Chiun Hsu
Chih-Hung Hsu
Ann-Lii Cheng
Tiffany Ting-Fang Shih
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 7/2017
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-016-4670-2

Other articles of this Issue 7/2017

European Radiology 7/2017 Go to the issue

Gastrointestinal

CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma

Cardiac

Clinical implementation of an emergency department coronary computed tomographic angiography protocol for triage of patients with suspected acute coronary syndrome

Computed Tomography

Should the automatic exposure control system of CT be disabled when scanning patients with endoaortic stents or mechanical heart valves? A phantom study

Gastrointestinal

Disappearing or residual tiny (≤5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required?

Ultrasound

High-resolution ultrasound visualization of the recurrent motor branch of the median nerve: normal and first pathological findings

Urogenital

European society of urogenital radiology (ESUR) guidelines: MR imaging of pelvic endometriosis